[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100587569":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":25,"centralContacts":30,"locations":40,"responsibleParty":57,"collaborators":59,"id":64,"slug":25,"hasResults":65,"nctId":66,"briefTitle":67,"officialTitle":67,"acronym":68,"eligibilityCriteria":69,"healthyVolunteers":65,"sex":70,"minAge":71,"maxAge":25,"enrollmentInfo":72,"targetDuration":25,"studyType":75,"phases":76,"briefSummary":78,"conditions":79,"keywords":81,"overallStatus":42,"whyStopped":25,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":92},{"fullName":5,"class":6},"Seoul National University Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Physiology-and imaging-guided PCI","EXPERIMENTAL","The goal is to achieve functional complete revascularization of major coronary arteries and their branches with diameters ≥2.5 mm. For lesions with ≥50% diameter stenosis, fractional flow reserve (FFR) measurement is mandatory. However, for severely stenotic lesions (\\>90%), revascularization may proceed at the operator's discretion without FFR assessment. In addition, intravascular ultrasound (IVUS) should be utilized during revascularization procedures and serve as an additional criterion for decision-making.\n\nAll patients in the intervention group will receive optimal medical therapy identical to that provided to the optimal medical therapy group following PCI.",[13],"Procedure: Physiology-and imaging-guided PCI",{"label":15,"type":16,"description":17,"interventionNames":18},"Optimal medical treatment","ACTIVE_COMPARATOR","All study participants will receive guideline-directed medical therapy, including an angiotensin receptor-neprilysin inhibitor (ARNi) or an angiotensin-converting enzyme inhibitor (ACEi) or angiotensin receptor blocker (ARB), a beta-blocker (carvedilol or bisoprolol), an aldosterone antagonist, and an SGLT2 inhibitor (empagliflozin or dapagliflozin). Medications will be administered even at low doses, as tolerated based on the patient's clinical status. Antiplatelet agents and statins will be maintained throughout the study period, and ezetimibe or PCSK9 inhibitors may be added as needed.\n\nIn addition, appropriate treatment will be provided for major cardiovascular risk factors such as hypertension, diabetes, and hyperlipidemia. Coexisting arrhythmias will be managed according to their respective guidelines. In the case of atrial fibrillation, active rate and rhythm control strategies will be implemented.",[19],"Drug: Optimal medical treatment",[21,26],{"type":22,"name":9,"description":23,"armGroupLabels":24,"otherNames":25},"PROCEDURE","The criteria for performing revascularization are as follows\n\n1. Lesions with ≥50% diameter stenosis and FFR ≤ 0.80, or lesions with severe stenosis (\\>90%)\n2. In vessels meeting the above criteria, IVUS findings consistent with either:\n\n   * Minimum lumen area (MLA) ≤ 3 mm²\n   * 3 mm² \\\u003C MLA ≤ 4 mm² and plaque burden \\>70%\n\nFor all target vessels and lesions identified for intervention, optimal revascularization should be pursued. The criteria for optimal revascularization are as follows, and operators are encouraged to achieve them:\n\n1. Post-PCI FFR \\> 0.86 in all treated vessels is recommended, with a minimum threshold of post-PCI FFR \\> 0.80 to achieve functional complete revascularization.\n2. Post-PCI ΔFFR (defined as \\[FFR at stent distal edge\\] - \\[FFR at stent proximal edge\\]) \\\u003C 0.05 is recommended.\n3. On IVUS, achieving a minimum stent area (MSA) \\> 5.5 mm² and MSA\u002Faverage reference lumen \\> 80% is recommended.",[9],null,{"type":27,"name":15,"description":28,"armGroupLabels":29,"otherNames":25},"DRUG","All study participants will receive guideline-directed medical therapy. Even for patients assigned to the optimal medical therapy group, revascularization may be performed during follow-up if clinically indicated. If such a decision is made prior to the primary endpoint assessment, a gadolinium-enhanced cardiac MRI will be performed at the time of consideration to reassess myocardial viability.",[15],[31,36],{"name":32,"role":33,"phone":34,"phoneExt":25,"email":35},"Doyeon Hwang, MD","CONTACT","82-10-7446-2779","cardiol.intv@gmail.com",{"name":37,"role":33,"phone":38,"phoneExt":25,"email":39},"Junpil Yun, MD","82-10-8001-9969","junpilyun@gmail.com",[41],{"facility":5,"status":42,"city":43,"state":44,"zip":45,"country":46,"countryCode":25,"cosmosGeoPoint":47,"geoPoint":52,"contacts":53},"RECRUITING","Seoul","Chongno-gu","03080","South Korea",{"type":48,"coordinates":49},"Point",[50,51],126.9784,37.566,{"lat":51,"lon":50},[54,56],{"name":32,"role":33,"phone":55,"phoneExt":25,"email":35},"01074462779",{"name":37,"role":33,"phone":38,"phoneExt":25,"email":39},{"type":58,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR",[60,62],{"name":61,"class":6},"Seoul National University Bundang Hospital",{"name":63,"class":6},"Seoul National University Boramae Hospital","100587569",false,"NCT06930092","RestoratIon of Myocardial Function by PeRcutaneous cOronary interVEntion in Patients With Ischemic CardioMyoPathy","IMPROVE-ICMP","Inclusion Criteria:\n\n* Subject must be ≥ 19 years\n* Subject is able to verbally confirm understandings of risks, benefits and treatment alternatives of receiving invasive physiologic or imaging evaluation and PCI and he\u002Fshe or his\u002Fher legally authorized representative provides written informed consent prior to any study related procedure.\n* Subject with LV ejection fraction \\\u003C40% from cardiac MRI\n* Subject with multivessel disease in major epicardial coronary artery disease or their major branches (vessel size of 2.5 mm or more than 2.5mm) considering coronary revascularization\n\nExclusion Criteria:\n\n* Subjects with more than 50% transmural extent of infarction on GE-MRI in more than 25% of the dysfunctional myocardial segments\n* Subject with suspicious of other cardiomyopathy (dilated cardiomyopathy, hypertrophic cardiomyopathy etc.)\n* Subject with recent myocardial infarction within 4 weeks\n* Subject with recent fatal arrhythmia (VT or VF) within 4 weeks\n* Subject with hemodynamically unstable state\n* Subject with complex coronary artery lesions, such as chronic total occlusions, in which complete revascularization is considered unfeasible\n* Subject for whom coronary artery bypass surgery is prioritized over coronary artery intervention\n* Subject with severe valvular heart disease requiring open heart surgery\n* Subject with history of coronary artery bypass surgery or valve surgery\n* Subject with expected life expectancy of less than 1 year\n* Subject considered ineligible for this study based on the investigator's discretion","ALL","19 Years",{"count":73,"type":74},158,"ESTIMATED","INTERVENTIONAL",[77],"NA","To compare the effects of physiology- and imaging-guided PCI combined with optimal medical therapy (OMT) versus OMT alone on the recovery of left ventricular systolic function in patients with ischemic cardiomyopathy and multivessel coronary artery disease.",[80],"Ischemic Cardiomyopathy",[82],"percutaneous coronary intervention","2026-04-21",{"date":85,"type":86},"2026-04-24","ACTUAL",{"date":88,"type":86},"2025-08-03",{"date":90,"type":74},"2029-04-30",{"name":5,"class":6},1]